Pharmacokinetics of tolfenamic acid in green sea turtles (Chelonia mydas) after intravenous and intramuscular administration.

Journal of Veterinary Pharmacology and Therapeutics
Natsuda RaweewanSaranya Poapolathep

Abstract

The present study aimed to evaluate the pharmacokinetic features of tolfenamic acid (TA) in green sea turtles, Chelonia mydas. Green sea turtles were administered single either intravenous (i.v.) or intramuscular (i.m.) injection of TA, at a dose of 4 mg/kg body weight (b.w.). Blood samples were collected at preassigned times up to 168 hr. The plasma concentrations of TA were measured using a validated liquid chromatography tandem mass spectrometry method. Tolfenamic acid plasma concentrations were quantifiable for up to 168 hr after i.v. and i.m. administration. The concentration of TA in the experimental green sea turtles with respect to time was pharmacokinetically analyzed using a noncompartment model. The Cmax values of TA were 55.01 ± 8.34 µg/ml following i.m. administration. The elimination half-life values were 32.76 ± 4.68 hr and 53.69 ± 3.38 hr after i.v. and i.m. administration, respectively. The absolute i.m. bioavailability was 72.02 ± 10.23%, and the average binding percentage of TA to plasma protein was 19.43 ± 6.75%. Based on the pharmacokinetic data, the i.m. administration of TA at a dosage of 4 mg/kg b.w. might be sufficient to produce a long-lasting anti-inflammatory effect (7 days) for green sea turtles. Ho...Continue Reading

References

Jan 1, 1984·European Journal of Clinical Pharmacology·P J PentikäinenA Penttilä
Apr 1, 1993·General and Comparative Endocrinology·K A Glennemeier, P Licht
Jan 1, 1997·Biopharmaceutics & Drug Disposition·H P LefebvreP L Toutain
Sep 15, 2004·Journal of Feline Medicine and Surgery·S A Robertson, P M Taylor
Dec 17, 2004·Journal of Veterinary Pharmacology and Therapeutics·P L Toutain, A Bousquet-Mélou
Jun 24, 2008·Lab Animal·Christoph Mans
Jan 18, 2011·Journal of the American Veterinary Medical Association·Bridget B BakerStephen M Johnson
Nov 14, 2012·Journal of Veterinary Pharmacology and Therapeutics·V Dinakaran, V K Dumka
May 31, 2014·Mediators of Inflammation·Piotr WojdasiewiczDariusz Szukiewicz
Sep 15, 2018·Scientific Reports·Chris WilcoxBritta Denise Hardesty
Oct 12, 2018·Journal of Veterinary Pharmacology and Therapeutics·Roipim MapongpengSaranya Poapolathep
Aug 10, 2019·Veterinary Anaesthesia and Analgesia·Orhan CorumKamil Uney
Nov 11, 2019·Journal of Veterinary Pharmacology and Therapeutics·Natsuda RaweewanSaranya Poapolathep

❮ Previous
Next ❯

Citations

Feb 19, 2021·Journal of Veterinary Pharmacology and Therapeutics·Erdinc TurkKamil Uney

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.